Exchange Traded Concepts, LLC Sage Therapeutics, Inc. Transaction History

Exchange Traded Concepts, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 17, 2023	BUY	$32.2 - $43.61 $29,430 - $39,859	914 Added 33.25%	3,663 $140,000
Q3 2022 Oct 07, 2022	BUY	$32.28 - $43.27 $11,168 - $14,971	346 Added 14.4%	2,749 $108,000
Q2 2022 Jul 20, 2022	BUY	$27.52 - $37.99 $42,793 - $59,074	1,555 Added 183.37%	2,403 $78,000
Q1 2022 Apr 26, 2022	BUY	$30.71 - $45.71 $26,042 - $38,762	848 New	848 $28,000
Q3 2021 Oct 18, 2021	SELL	$40.26 - $57.37 $11,474 - $16,350	-285 Closed	0 $0
Q2 2021 Jul 30, 2021	BUY	$54.88 - $79.29 $15,640 - $22,597	285 New	285 $16,000
Q1 2021 Apr 20, 2021	SELL	$70.65 - $96.76 $603,280 - $826,233	-8,539 Closed	0 $0
Q4 2020 Jan 19, 2021	BUY	$58.41 - $89.06 $498,762 - $760,483	8,539 New	8,539 $739,000

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

Stay updated on Exchange Traded Concepts, LLC with notifications on news.